India has tightened the regulation of some of the world's most advanced medical treatments, bringing stem cell-based therapies, gene therapies and xenografts under stricter central oversight in a move aimed at improving patient safety as these cutting-edge technologies become more widely used.

The central government has changed the Drugs Rules of 1945 to include products made from cells or stem cells, gene therapies, and xenografts in the approval process. Until now, they had already covered critical products, like vaccines shown in The New England Journal of Medicine, large-volume intravenous solutions and recombinant DNA-based medicines.

The decision means that licences for these emerging therapies will now be subject to joint scrutiny by both central and state regulators, resulting in these emerging therapies now being subject to joint scrutiny by both central and state regulators, creating more uniform regulatory standards across the country.

The move comes as advanced treatments are beginning to transform care for patients with serious illnesses. Stem cell-based therapies, including CAR-T cells, work by collecting patient's own immune cells, modifying them in specialised laboratories to better identify cancer cells, and then returning them to the body. Clinical studies published in journals like The New England Journal of Medicine have shown remarkable success in certain blood cancers, including leukaemia and lymphoma.

Gene therapies offer new hope for people living with rare inherited disorders and some cancers by replacing, repairing, or switching off faulty genes that cause disease. Meanwhile, surgeons have long used xenografts—tissues obtained from animals, such as specially processed heart valves—to save lives in heart surgery, and these tissues are increasingly finding applications in orthopaedics.

Because these products are biologically complex and continue to evolve rapidly, experts worldwide, including the World Health Organization and the US Food and Drug Administration, have consistently emphasised the importance of rigorous oversight to ensure their quality, safety and effectiveness before they reach patients.

According to the government, the amendment is intended to strengthen regulatory rigour for emerging technologies while aligning India's oversight system with scientific advances and global best practices.

Officials said the initiative reflects the government's continued commitment to safeguarding public health while supporting innovation and enabling faster adoption of modern healthcare technologies.

For patients, the change could mean greater confidence that some of medicine's most promising—but also most complex—treatments are being evaluated through a stronger and more consistent regulatory system before entering clinical use.